The Next Generation Biotech Media
By T. Chakraborty, Ph.D. The “INdividualized Therapy FOr Relapsed Malignancies in Childhood” (INFORM) registry aims to create a personalized database for progressive or refractory pediatric cancer patients. Dr. Cornelis M. …
Read More
By Ruchi Jhonsa, Ph.D. Bladder cancer is the 6th most common cancer in the US and is responsible for 200,000 deaths globally in 2018. The current standard of care for …
Read More
By T. Chakraborty, Ph.D. Breast cancer is one of the most common causes of cancer in women, resulting in 1 out of 8 patients in the US, developing an invasive …
Read More
By Rajaneesh K. Gopinath, Ph.D. Within days of Clovis Oncology’s regulatory win for Rubraca, Lynparza bagged FDA authorization for the treatment of metastatic, castration-resistant prostate cancer (mCRPC), becoming only the …
Read More
By Pavel Ryzhov, Ph.D. Since the discovery of HIV in 1981, the search for a preventive agent has been a pursuit for generations of scientists. The strides made in our …
Read More
By Ruchi Jhonsa, Ph.D. Three years back, when the San Diego-based biotech spun out of Scripps Research Institute in La Jolla, California, it decided to expand its cutting edge discovery …
Read More
By Ruchi Jhonsa, Ph.D. At the 23rd Annual virtual Meeting of the American Society of Gene and Cell Therapy, Intellia Therapeutics, a leading genome editing company, presented some key data …
Read More
By T. Chakraborty, Ph.D. Gastric cancer is difficult to treat and is the third most common cause of cancer mortality. With a 32% five-year survival rate, it is estimated to …
Read More
The Japanese drug manufacturer’s plans to launch the world’s first non-steroidal JAK inhibitor against atopic dermatitis in the country gets a huge boost with this development. On April 22, Japan-based …
Read More
By T. Chakraborty, Ph.D. On April 21st, AbbVie, one of the largest research-based global biopharmaceutical company, announced the USFDA approval for Imbruvica (ibrutinib) in combination with rituximab for treating chronic …
Read More